Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| CJC-1295 (without DAC / Mod GRF 1-29) | LL-37 (Cathelicidin) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. |
| Timing | Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection. | Morning administration preferred for immune support. Topical application directly to wound sites. |
| Cycle Duration | 12-24 week cycles with 4-8 week breaks. | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.
12-24 week cycles with 4-8 week breaks.
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →